Oct 1, 2020 9:18 PM ET
iCrowd Newswire – Oct 1, 2020
Zion Market Research has published a new report titled “Lipid Disorder Treatment Market by Drug Type (Pravastatin, Simvastatin, Rosuvastatin, Fluvastatin, Atorvastatin and Other Drugs); by Indication (Heterozygous Familial Hypercholesterolemia, Familial Hypertriglyceridemia, Familial Dysbetalipoproteinemia, Familial Defective Apolipoprotein B-100, Familial Combined Hyperlipidemia and Other Indications); by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 – 2025”. According to the report, global demand for lipid disorder treatment market was valued at approximately USD 22.42 billion in 2018, and is expected to generate revenue of around USD 38.04 billion by end of 2025, growing at a CAGR of around 7.9% between 2019 and 2025.
Lipids also known as lipoproteins are fats those circulate in the bloodstream. These include high-density lipoproteins (HDL), low-density lipoproteins (LDL) and triglycerides. Lipid disorder is term coined for a wide range of metabolic conditions that mainly impact the lipid levels in the blood. Symptoms of lipid disorders are usually heightened levels of lipoproteins, cholesterol, and/or triglycerides in the blood which may be associated with increased risk of cardiovascular disorders. Majority of lipid disorders are acquired due to various factors such as obesity, sedentary lifestyle, inactivity, lack of exercise, and alcoholism etc. Congenital factors are less common. Lipid lowering agents mainly statins are used for lipid disorder treatment along with lifestyle modifications.
Request For Free Sample Report @ https://www.zionmarketresearch.com/sample/lipid-disorder-treatment-market
The lipid disorder treatment market growth is fueled by various factors such as growing prevalence of lipid disorders related to LDL and triglyceride, changing eating habits, rising prevalence of cardiovascular diseases, and greater adoption of sedentary lifestyle worldwide. Additionally, increasing elderly population, emphasis on development of novel treatment options by major players, and growing health awareness are some other factors that support the market growth. Evolving markets with increasing aging population are expected to open new growth avenues for major market players in the global lipid disorder treatment.
The lipid disorder treatment market is segmented based on distribution channel, indication, drug type, and region. Based on drug type, market is segmented into simvastatin, pravastatin, atorvastatin, fluvastatin, rosuvastatin, and other drugs. Atorvastatin was the largest drug type segment in 2018. Increased use of atorvastatin is mainly due to its effectiveness against bad cholesterol, controlling triglyceride levels and treatment of cardiovascular disorders. On the other hand, rosuvastatin drug type segment is projected to exhibit fastest growth over the forecast period.
Based on indication, global lipid disorder treatment market is categorized into familial dysbetalipoproteinemia, heterozygous familial hypercholesterolemia, familial hypertriglyceridemia, familial combined hyperlipidemia, familial defective apolipoprotein b-100, and other indications.
Retail pharmacies, hospital pharmacies, and online pharmacies are the distribution channels for lipid disorder treatment market. In 2018, largest market share was held by retail pharmacies owing to large number of retail pharmacies worldwide. Online pharmacies are projected to exhibit highest growth in the coming years.
At regional level, North America led the global lipid disorder treatment market in 2018. This large share is attributed to growing prevalence of lipid disorders, growing prevalence of cardiovascular diseases associated with increased lipid levels in the blood, and increasing health awareness. Europe was second leading regional market. Various factors such as availability of developed infrastructure, growing prevalence of lipid disorders and increasing health awareness are major factors that support market growth in this region. Latin America is projected to witness modest growth during the forecast period. Asia Pacific region is forecasted to witness swift growth over the forecast period. Growing elderly population base with increasing prevalence of metabolic disorders, increasing health awareness and spending, and sedentary lifestyle are important factors that boost growth of lipid disorder treatment market in Asia Pacific. Moderate growth is projected for Middle East and Africa in the coming years.
Major players included in the report are Teva Pharmaceuticals, Mylan Pharmaceuticals, Novartis AG, Kowa Pharmaceuticals America, Inc., Astrazeneca Plc, Pfizer, Inc., Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Emcure Pharmaceuticals Ltd., Merck & Co. and Wockhardt Limited among others.
The report segment of global lipid disorder treatment market as follows:
Global Lipid Disorder Treatment Market: By Drug Type
- Other Drugs
Global Lipid Disorder Treatment Market: By Indication
- Heterozygous Familial Hypercholesterolemia
- Familial Hypertriglyceridemia
- Familial Dysbetalipoproteinemia
- Familial Defective Apolipoprotein B-100
- Familial Combined Hyperlipidemia
- Other Indications
Global Lipid Disorder Treatment Market: By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Lipid Disorder Treatment Market: By Region
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Inquire more before buying this report @ https://www.zionmarketresearch.com/inquiry/lipid-disorder-treatment-market
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: [email protected]
Keywords: Lipid Disorder Treatment Market